Avicanna Inc (TSX:AVCN, OTCQX:AVCNF) said it has launched Avicenna Academy, a no-cost medical cannabis education portal for health care professionals (HCPs).
The portal is designed to support HCPs, through education and practical information, on the potential use of medical cannabis, with a view towards expanding access as well as measuring patient outcomes.
"We are excited about the launch of this platform as a resource that facilitates information and education to potentially improve patient outcomes and foster further collaboration with the medical community," said Aras Azadian, Avicanna CEO, in a statement.
READ: Avicanna collaborates with University of Toronto to expand its epilepsy research program
The Avicenna Academy is designed to address the potential gaps in understanding cannabinoid-based products while making available resources and information, which may be tools for the medical community, the company said.
Towards that goal, Avicanna's medical team has combined its research and development expertise with cannabinoid formulations utilizing advanced drug delivery systems, it added.
The company has been able to develop various educational resources such as downloadable guides, online modules, and access to discussions with key opinion leaders across a range of medical specialities thanks to its practical experience in delivering RHO Phyto medical cannabis products through established medical portals, pharmacies and major hospitals both in Canada and international markets.
The portal currently includes a range of resources, including HCPs guidelines and supporting information regarding medical authorization documentation for patients in Canada.
The preliminary set of modules cover a range of topics, including the history of medical cannabis use, the endocannabinoid system, potential therapeutic targets, the current state of evidence, dosing and titration overview, as well as case studies and practical use.
The Avicenna Academy plans to expand offerings that are reflective of ongoing research in the field, and indication-specific modules in collaboration with Canadian and international key opinion leaders and experts.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments.
The company has an established scientific platform, including R&D and clinical development that has led to the commercialization of more than 30 products under the categories of:
- Medical cannabis and wellness products: Marketed under the RHO Phyto brand, these are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (CBD) and tetrahydrocannabinol (THC). The product portfolio includes oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. It is marketed with consumer, patient and medical-community education and training.
- Pharmaceutical pipeline: Leveraging its scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Its first pharmaceutical preparation, Trunerox, is in the drug registration stage in South America.
Contact the author at jon.hopkins@proactiveinvestors.com